ArticleFrontiers in oncology2026
Cancer-associated fibroblast activation protein in Appalachian women with uterine cervix cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in γδ T cell-mediated immune surveillance in cervical cancer.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: [ Methods: We examined a series of 37 uterine cervix cancer paraffin-embedded tumors to determine whether this tumor type expresses FAP at a sufficient cell proportion and staining intensity for an immunoreactive score (IRS) of six or higher, as [ Results: The results show that 28 of 34 (82%) uterine cervix cancer tumors with evaluable desmoplastic stroma had cancer-associated fibroblasts expressing FAP. Twenty (59%) tumors scored at an IRS six or higher. Primary tumors from patients with stage IVB disease at diagnosis (n=11) or metastatic tumors (n=6) had cancer-associated fibroblasts expressing FAP most often (76%). Discussion: Cancer-associated fibroblast FAP immunoreactivity in this series indicates that [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.